Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]

Appeal

Appeal letter - Gilead : Appeal letter (MSWord 180 KB)

Scrutiny letter - NICE : Scrutiny letter (MSWord 87 KB)

Response to scrutiny letter - Gilead : Response to scrutiny letter (MSWord 142 KB)

NICE's final response : NICE's final response (MSWord 104 KB)

Appeal letter - Patient Groups : Appeal letter (MSWord 106 KB)

Scrutiny letter - NICE : Scrutiny letter (MSWord 80 KB)

Response to scrutiny letter - Patient Groups : Response to scrutiny letter (MSWord 113 KB)

Final draft guidance

Final draft guidance (PDF 260 KB)

Equality impact assessment (downloadable version) (PDF 123 KB)

Committee papers (PDF 1.81 MB)

Draft guidance

Public committee slides (PowerPoint 1.82 MB)

Committee papers (PDF 3.91 MB)

Equality impact assessment (downloadable version) (PDF 121 KB)

Draft guidance (downloadable version) (PDF 247 KB)

Final scope (PDF 126 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 289 KB)

Equality impact assessment (scoping) (PDF 126 KB)

Draft scope post referral (PDF 132 KB)